Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cubilin-amnionless receptor complex, commonly known as Cubam, is a multimeric endocytic receptor essential for the absorption of specific ligands in the intestine and kidney [1, 3]. It is composed of two primary subunits: cubilin, which provides the ligand-binding domains, and amnionless, which anchors the complex to the plasma membrane and initiates endocytosis [2, 5]. In the terminal ileum, Cubam is the sole receptor responsible for the uptake of the intrinsic factor-vitamin B12 complex, a process vital for maintaining systemic cobalamin levels [1, 4]. In the renal proximal tubules, the complex facilitates the reabsorption of various proteins from the glomerular filtrate, including albumin and transferrin, to prevent proteinuria [3, 4]. Mutations in the genes encoding either subunit result in Imerslund-Gräsbeck syndrome, characterized by megaloblastic anemia and persistent proteinuria [1, 6]. While not a typical target for pharmacological inhibition, Cubam is the primary pathway for the therapeutic administration of oral vitamin B12 [8]. Furthermore, its role in protein trafficking makes it a subject of interest for targeted drug delivery and a potential biomarker for renal health and certain malignancies [2, 4].
The receptor complex facilitates the receptor-mediated endocytosis of the intrinsic factor-vitamin B12 complex in the ileum and the reabsorption of low-molecular-weight proteins in the renal proximal tubules [1, 3, 4].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cubilin-amnionless receptor complex (Cubam).